StockNews.AI
CMRX
StockNews.AI
151 days

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

1. FDA accepted Chimerix's NDA for dordaviprone, pivotal for patients with glioma. 2. Jazz Pharmaceuticals plans to acquire Chimerix for $8.55 per share. 3. Chimerix reported a net loss increase in Q4 2024 compared to Q4 2023. 4. Acquisition expected to close Q2 2025, enhancing dordaviprone market entry. 5. Research expenses rose, impacting short-term financial performance.

Earnings
+0.35%Current Return
VS
-0.27%S&P 500
$8.4703/21 06:05 AM EDTEvent Start
$8.503/24 06:21 AM EDTLatest Updated
11m saved
Insight
Article

FAQ

Why Bullish?

The FDA NDA acceptance and pending acquisition could drive significant interest and investment opportunities. Historical examples, like ARNA's acquisition, showcase market reactions to strategic mergers aiming to commercialize new therapies.

How important is it?

The news contains critical developments, including NDA progress and acquisition plans, crucial for CMRX's future.

Why Long Term?

The anticipated benefits from the acquisition and potential drug approval may take time to reflect in stock performance, similar to BRMS's gradual uplifts post-acquisition announcements.

Related Companies

JAZZARNABRMS
March 21, 2025 06:00 ET  | Source: Chimerix, Inc. New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chimerix and offers renewed hope for patients diagnosed with this life-threatening cancer," said Mike Andriole, Chief Executive Officer of Chimerix. “Our mission to bring dordaviprone to patients globally is greatly enhanced by the pending acquisition of Chimerix by Jazz. We continue to prepare to bring dordaviprone to patients in need as quickly as possible." Fourth Quarter 2024 Financial ResultsChimerix’s balance sheet at December 31, 2024 included $140.1 million of capital available to fund operations, no outstanding debt, and approximately 92.2 million outstanding shares of common stock. Chimerix reported a net loss of $23.0 million, or $0.25 per basic and diluted share, for the fourth quarter of 2024, compared to a net loss of $18.2 million, or $0.20 per basic and diluted share for the fourth quarter of 2023. Research and development expenses increased to $17.7 million for the fourth quarter of 2024, compared to $15.6 million for the same period in 2023. General and administrative expenses increased to $7.0 million for the fourth quarter of 2024, compared to $5.2 million for the same period in 2023. The increase was mainly due to increased spending on commercial launch preparations. Full Year 2024 Financial ResultsChimerix reported a net loss of $88.4 million, or $0.99 per basic and diluted share, for the year ended December 31, 2024 compared to a net loss of $82.1 million, or $0.93 per basic and diluted share for the year ended December 31, 2023. Research and development expenses increased to $74.6 million for the year ended December 31, 2024, compared to $68.8 million for the year ended December 31, 2023. General and administrative expenses decreased to $22.2 million for the year ended December 31, 2024, compared to $24.6 million for the year ended December 31, 2023. Transaction with JazzOn March 5, 2025, Chimerix and Jazz announced that the companies have entered into a definitive merger agreement under which Jazz has agreed to acquire Chimerix for $8.55 per share in cash, for a total consideration of approximately $935 million. The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix’s voting common stock and other conditions. In light of the pending acquisition by Jazz, Chimerix will not hold a conference call to discuss its fourth quarter and full year 2024 earnings. About Chimerix Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things: Jazz’s proposed acquisition of Chimerix, the anticipated occurrence, manner and timing of the proposed tender offer, the closing of the proposed acquisition and the prospective benefits of the proposed acquisition; the initial potential PDUFA timing; and other statements that are not historical facts. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are: uncertainties as to the timing of the tender offer; uncertainties as to how many of Chimerix’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction (or only grant approval subject to adverse conditions or limitations); the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the possibility that the transaction does not close; the risk that competing offers or acquisition proposals will be made; the effects of the transaction on relationships with employees, customers, suppliers, other business partners or governmental entities; significant transaction costs; the risk of litigation and/or regulatory actions related to the proposed acquisition; effectively launching and commercializing products and product candidates such as dordaviprone, if approved; the successful completion of development and regulatory activities with respect to dordaviprone; obtaining and maintaining adequate coverage and reimbursement; the time-consuming and uncertain regulatory approval process, including the risk that Chimerix’s NDA for dordaviprone seeking accelerated approval for treatment of H3 K27M-mutant diffuse glioma in adult and pediatric patients with progressive disease following prior therapy may not be approved by FDA in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials of dordaviprone; global economic, financial, and healthcare system disruptions; and additional risks set forth in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT:Will O’ConnorStern Investor Relations212-362-1200ir@chimerix.comwill@sternir.com CHIMERIX, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)                 December 31, December 31,       2024   2023  ASSETS     Current assets:      Cash and cash equivalents $31,049  $27,661   Short-term investments, available-for-sale  100,594   155,174   Accounts receivable  57   4   Prepaid expenses and other current assets  4,251   6,271    Total current assets  135,951   189,110  Long-term investments  8,475   21,657  Property and equipment, net of accumulated depreciation  417   224  Operating lease right-of-use assets  951   1,482  Other long-term assets  214   301     Total assets $146,008  $212,774           LIABILITIES AND STOCKHOLDERS' EQUITY     Current liabilities:      Accounts payable $3,938  $2,851   Accrued liabilities  19,933   15,592    Total current liabilities  23,871   18,443  Line of credit commitment fee  -   125  Lease-related obligations  458   1,177     Total liabilities  24,329   19,745           Stockholders’ equity:      Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2024 and      2023; no shares issued and outstanding as of December 31, 2024 and 2023  -   -   Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2024 and     2023; 92,209,175 and 88,929,300 shares issued and outstanding as of December 31, 2024     and 2023, respectively  92   89   Additional paid-in capital  1,005,475   988,457   Accumulated other comprehensive gain, net  23   7   Accumulated deficit  (883,911)  (795,524)   Total stockholders’ equity  121,679   193,029     Total liabilities and stockholders’ equity $146,008  $212,774            CHIMERIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS  (in thousands, except share and per share data)                        Three Months Ended December 31, Years Ended December 31,        2024   2023   2024   2023  Revenues:          Contract and grant revenue $57  $4  $212  $275   Licensing revenue  -   -   -   49    Total revenues  57   4   212   324  Operating expenses:          Research and development  17,656   15,644   74,574   68,788   General and administrative  6,953   5,170   22,205   24,601    Total operating expenses  24,609   20,814   96,779   93,389     Loss from operations  (24,552)  (20,810)  (96,567)  (93,065) Other income:          Interest income and other, net  1,598   2,649   8,180   10,970      Net loss   (22,954)  (18,161)  (88,387)  (82,095) Other comprehensive (loss) income:          Unrealized (loss) income on investments, net  (235)  632   16   344      Comprehensive loss $(23,189) $(17,529) $(88,371) $(81,751) Per share information:          Net loss, basic and diluted $(0.25) $(0.20) $(0.99) $(0.93)                Weighted-average shares outstanding, basic and diluted  90,261,484   88,910,300   89,699,074   88,604,026  

Related News